胃肠舒治疗糖尿病性胃轻瘫的临床观察

Clinical Observation on Effect of Weichangshu in Treating Diabetic Gastroparesis

目的观察胃肠舒治疗糖尿病性胃轻瘫 (DGP)的效果。方法 96例DGP患者 ,随机均分为两组 ,两组原控制血糖方案不变 ,治疗组口服胃肠舒 ,对照组口服贝络纳 ,疗程均为 4周。于治疗前后进行临床证候疗效评价、空腹和餐后 2h血糖测定 ,胃窦十二指肠消化间期移行性复合运动波 (MMC)和胃电图 (EGG)检测。结果两组患者临床疗效相仿 ,经统计学处理差异无显著性。两组患者的MMCⅡ相持续时间、Ⅲ相持续时间和收缩波幅 ,与治疗前比较差异均有显著性 (P <0 .0 5 ) ;胃电活动 (主要表现为主频率比增加、主功率比增强 )与治疗前比较差异也均有显著性 (P <0 .0 5或P <0 .0 1)。胃肠舒还可促进餐后 2h血糖下降。结论胃肠舒与贝络纳均具有促胃动力和降血糖的双重作用 ,但不良反应较后者少。

observe the effect of Weichangshu (WCS) in treating diabetic gastroparesis (DGP). MethodsNinety-six patients with DGP were randomly divided into two groups. Besides the same conventional blood glucose controlling regimen was given to both groups, WSC was given to the treated group and Mosapride Citrate tablet to the control group additionally.The treatment course for them was 4 weeks. Therapeutic effect on clinical syndromes was assessed, the fasting and 2-hr postprandial blood glucose, antro-duodenal interdigestive migrating motor complex (MMC) and electrogastrogram (EGG) were measured before and after treatment. ResultsThe therapeutic effect in the two groups were similar with no statistical significant difference. The time of MMC phaseⅡ was shortened, time of MMC phase Ⅲ prolonged, and the constriction amplitude of which increased after treatment in both groups, showing significant difference as compared to those before treatment ((P<)0.05). EGG were significantly changed after treatment mainly manifested as increase of proportional dominant frequency (PDF) and strengthening of proportional dominant amplitude (PDP ) (P<0.05 or P<0.01). Besides, WSC also promoted the decrease of post-prandial blood glucose. ConclusionWSC has dual effect in promoting gastric motility and decreasing blood glucose, with less adoerst reaction.